Discovery of potent and simplified piperidinone-based inhibitors of the MDM2-p53 interaction

ACS Medicinal Chemistry Letters

Volumn 5, Issue 8, 2014, Pages 894-899

  Yu, Ming ^a   Wang, Yingcai ^a   Zhu, Jiang ^a   Bartberger, Michael D ^a   Canon, Jude ^a   Chen, Ada ^a   Chow, David ^a   Eksterowicz, John ^a   Fox, Brian ^a   Fu, Jiasheng ^a   Gribble, Michael ^a   Huang, Xin ^a   Li, Zhihong ^a   Liu, Jiwen ^a   Lo, Mei Chu ^a   McMinn, Dustin ^a   Oliner, Jonathan D ^a   Osgood, Tao ^a   Rew, Yosup ^a   Saiki, Anne Y ^a   Shaffer, Paul ^a   Yan, Xuelei ^a   Ye, Qiuping ^a   Yu, Dongyin ^a   Zhao, Xiaoning ^a   Zhou, Jing ^a   Olson, Steven H ^a   Medina, Julio C ^a   Sun, Daqing ^a   more..

^a AMGEN INC   (United States)

Author keywords

MDM2; p53; piperidinone; protein protein interaction; pyridine

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PIPERIDONE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; SERUM; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

EID: 84906258076     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500142b     Document Type: Article

References (15)

1. Chen, J.; Wu, X.; Lin, J.; Levine, A. J. MDM2 inhibits the G1 arrest and apoptosis function of the p53 tumor suppressor protein Mol. Cell. Biol. 1996, 16, 2445-2452
2. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug Discovery 2008, 7, 979-987
3. Chene, P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy Nat. Rev. Cancer. 2003, 3, 102-109
4. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network Nature 2000, 408, 307-310
5. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Nature 1992, 358, 80-83
6. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009
7. Hainaut, P.; Hollstein, M. p53 and human cancer: the first ten thousand mutations Adv. Cancer Res. 1999, 77, 81-137
8. Zhao, Y.; Yu, S.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Shargary, S.; Bernard, D.; Li, X.; Zhao, T.; Zou, P.; Sun, D.; Wang, S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice J. Med. Chem. 2013, 56, 5553-5561
9. Ding, Q.; Zhang, Z.; Liu, J.-J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X.-J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013, 56, 5979-5983
10. Sun, D.; Li, Z.; Rew, Y.; Gribble, M.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.; Fu, J.; Gonzalez, A. Z.; Gonzalez-Lopez De Turiso, F.; Houze, J. B.; Huang, X.; Jiang, M.; Jin, L.; Kayser, F.; Liu, J.; Lo, M.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J. D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.; Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, J.; Zhu, J.; Olson, S. H.; Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development J. Med. Chem. 2014, 57, 1454-1472
11. Information from www.clinicaltrials.gov. (a) RG7112 (Hoffmann-La Roche). (b) RG7388 (Hoffmann-La Roche). (c) SAR299155 (Sanofi). (d) MK-8242 (Merck). (e) AMG 232 (Amgen). (f) CGM-097 (Novartis). (g) DS-3032b (Daiichi Sankyo).
12. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J. J.; Zhao, C.; Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development ACS Med. Chem. Lett. 2013, 4, 466-469
13. Ding, Q.; Zhang, Z.; Liu, J. J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X. J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Zoran M. Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013, 56, 5979-5983
14. Carry, J.; Garcia-Echeverria, C. Inhibitors of the p53/hdm2 protein-protein interaction: path to the clinic Bioorg. Med. Chem. Lett. 2013, 23, 2480-2485
15. Rew, Y.; Sun, D.; Gonzalez Lopez De Turiso, F.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; Kopecky, D. J.; Li, Y.; Lo, M.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Structure-based design of novel inhibitors of the MDM2-p53 interaction J. Med. Chem. 2012, 55, 4936-4954